8:00 AM ET
8-K
M&A Deal
Acrivon Therapeutics M&A Deal with Aqilion AB
Acrivon Therapeutics has acquired a portfolio of immunology and inflammation (I&I) assets from Swedish biotech Aqilion AB, including the Phase 2-ready oral JAK1 inhibitor ACR-525 and a preclinical PKCθ inhibitor program. The deal establishes I&I as a new strategic pillar for Acrivon, which plans to apply its AP3 precision medicine platform to these assets for indications such as Eosinophilic esophagitis (EoE).
- Counterparty
- Aqilion AB